Patent application number | Description | Published |
20080221152 | 4-(HETEROARYL-METHYL AND SUBSTITUTED HETEROARYL-METHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS - Compounds of Formula 1 | 09-11-2008 |
20080221186 | 4-(substituted cycloalkylmethyl) Imidazole-2-Thiones, 4-(substituted cycloalkenylmethyl) Imidazole-2-Thiones, 4-(substituted cycloalkylmethyl) Imidazol-2-Ones and 4-(substituted cycloalkenylmethyl) Imidazole-2-Ones and related compounds - Compounds of Formula 1 | 09-11-2008 |
20080260832 | SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR PREVENTING RETINAL DYSFUNCTION - Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure. | 10-23-2008 |
20080299178 | SUSTAINED RELEASE INTRAOCULAR IMPLANTS AND METHODS FOR PREVENTING RETINAL DYSFUNCTION - Biocompatible intraocular microspheres and implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to treat or to prevent the occurrence of one or more ocular conditions, to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like, to enhance normal retinal function and/or to lower intraocular pressure. | 12-04-2008 |
20080319013 | 4-(SUBSTITUTED CYCLOALKYLMETHYL) IMIDAZOLE-2-THIONES, 4-(SUBSTITUTED CYCLOALKENYLMETHYL) IMIDAZOLE-2-THIONES, 4-(SUBSTITUTED CYCLOALKYLMETHYL) IMIDAZOLE-2-ONES AND, 4-(SUBSTITUTED CYCLOALKYLMETHYL) IMIDAZOLE-2-ONES AND RELATED COMPOUNDS - Compounds of Formula 1 | 12-25-2008 |
20090176828 | 4-(CONDENSED CYCLICMETHYL)-IMIDAZOLE-2-THIONES ACTING AS ALPHA2 ADRENERGIC AGONISTS - Compounds of Formula 1 | 07-09-2009 |
20090176845 | SUBSTITUTED 2-AMINOTETRALIN DERIVATIVES AS SELECTIVE ALPHA 2B AGONIST - Substituted 2-aminotetralin derivatives as selective alpha 2B agonists includes a compound represented by Formula 1: | 07-09-2009 |
20100081631 | METHODS AND COMPOSITIONS FOR TREATING GASTROINTENSTIAL DISORDERS - Methods are provided directed to administering a therapeutically effective amount of a prostaglandin EP | 04-01-2010 |
20100129435 | Methods and compositions for treatment of ocular neovascularization and neural injury - Methods and compositions for the treatment of ocular neovascularization and macular degeneration. The invention includes combining photodynamic therapy with administration of a neuroprotectant and a neovascularization inhibitor. | 05-27-2010 |
20100298395 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME - Compounds of Formula 1 | 11-25-2010 |
20110251201 | Sustained release intraocular implants and methods for preventing retinal dysfunction - Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like. | 10-13-2011 |
20110312886 | TGF- AND METHODS OF TREATING OCULAR AND OTHER DISEASES - Disclosed herein is a method of treating ocular and systemic conditions by administering a TGF-β. | 12-22-2011 |
20110318303 | IL-10 AND METHODS OF TREATING OCULAR AND OTHER DISEASES - Disclosed herein TPV1 is a method of treating ocular and systemic conditions by administering IL-10 and TPV134R polypeptides. | 12-29-2011 |
20120046332 | COMPOSITIONS AND METHODS FOR TREATING CORNEAL HAZE - Disclosed herein are compositions and methods for treating corneal haze. Compositions and methods of use comprise therapeutically effective amounts of compounds that agonize the EP2 and/or EP4 receptor. Administration of the disclosed compounds can prevent and treat corneal haze development. | 02-23-2012 |
20120136011 | COMPOUNDS AND METHODS FOR SKIN REPAIR - The disclosure provides compositions and methods for treating a skin blemish. The compositions comprise a therapeutically effective amount of a compound useful for treating skin blemishes such as wounds, scars and wrinkles. | 05-31-2012 |
20120142675 | Methods for Treating Diseases of the Retina - Disclosed herein is a method of treating disorders of the retina comprising administering to a patient in need of such treatment a compound selected from the group consisting of olanzapine, certain of its metabolites, clozapine, and n-desmethyl clozapine. | 06-07-2012 |
20120196911 | UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME - Compounds of Formula 1 | 08-02-2012 |
20120259413 | DEVICES, COMPOSITIONS AND METHODS UTILIZING EP4 AND EP2 RECEPTOR AGONISTS FOR PREVENTING, REDUCING OR TREATING CAPSULAR CONTRACTURE - Provided are devices, compositions and methods utilizing EP | 10-11-2012 |
20130156766 | TREATMENT OF DRY AGE RELATED MACULAR DEGENERATION - A method of treating dry age related macular degeneration (“AMD”) comprising administration to the eye of an individual in need thereof of a therapeutically effective amount of an anti-endoglin agent. | 06-20-2013 |
20130236526 | Sustained Release Intraocular Implants and Methods for Preventing Retinal Dysfunction - Biocompatible intraocular implants include an alpha-2 adrenergic receptor agonist and a polymer associated with the alpha-2 adrenergic receptor agonist to facilitate release of the alpha-2 adrenergic receptor agonist into an eye for an extended period of time. The alpha-2 adrenergic receptor agonist may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. The implants may be placed in an eye to prevent the occurrence of one or more ocular conditions, or to reduce one or more symptoms of an ocular condition, such as an ocular neurosensory disorder and the like. | 09-12-2013 |
20130323202 | METHODS OF TREATING OCULAR AND OTHER DISEASES WITH SYN-134R POLYPEPTIDE - Disclosed herein TPV1 is a method of treating ocular and systemic conditions by administering IL-10 and TPV134R polypeptides. | 12-05-2013 |
20140142042 | SKIN WOUND HEALING AND SCAR REDUCTION WITH PROSTAGLANDIN EP4 AGONIST COMBINATIONS - A combination of a prostaglandin EP4 agonist and an effective amount of: a prostaglandin EP2 agonist, a skin growth factor, a small peptide, a small inhibitory RNA targeting excess chronic inflammation or fibrosis, a cytokine with beneficial anti-inflammatory activity, an adenosine A2a receptor agonist, an anti-oxidant, or a combination thereof, may be used to treat skin wounds or scars. | 05-22-2014 |